1. 首页
  2. 产品目录

DOXO-EMCH

DOXO-EMCH （订货以英文为准）

编号：D124959
CAS号：151038-96-9
分子式：C37H42N4O13
分子量：750.75
货号 品牌 包装 目录价 您的价格 库存 数量 购买
D124959-20mg 阿拉丁 20mg ¥4119.90
请登录
D124959-10mg 阿拉丁 10mg ¥2677.90
请登录
D124959-50mg 阿拉丁 50mg ¥9269.90
请登录
D124959-100mg 阿拉丁 100mg ¥13436.90
请登录
产品名称 DOXO-EMCH
中文名称 DOXO-EMCH
CAS号 151038-96-9
分子式（M.F.） C37H42N4O13
分子量（M.W.） 750.75
储存条件 -20°C储存
溶解性DMSO
存贮条件储存温度-20°C
生化机理DOXO-EMCH (151038-96-9) is defined as Double bond geometry unknown, also can be called as INNO-206 (1361644-26-9) with Double bond geometry (2E). INNO-206 (Aldoxorubicin) is the 6-maleimidocaproyl hydrazone derivative prodrug of the anthracycline antibiotic doxorubicin (DOXO-EMCH) with antineoplastic activity. Following intravenous administration, doxorubicin prodrug INNO-206 binds selectively to the cysteine-34 position of albumin via its maleimide moiety. Doxorubicin is released from the albumin carrier after cleavage of the acid-sensitive hydrazone linker within the acidic environment of tumors and, once located intracellularly, intercalates DNA, inhibits DNA synthesis, and induces apoptosis. Albumin tends to accumulate in solid tumors as a result of high metabolic turnover, rapid angiogenesis, hyervasculature, and impaired lymphatic drainage. Because of passive accumulation within tumors, this agent may improve the therapeutic effects of doxorubicin while minimizing systemic toxicity. In a phase I study, INNO-206 showed a good safety profile at doses up to 260 mg/m2 doxorubicin equivalents. Although not the primary end point of the phase I study, INNO-206 was able to induce tumor regressions in breast cancer, small cell lung cancer and sarcoma.
搜索质检报告(COA)
搜索MSDS
相关产品